Bowen Li

Nucleic acids, also known as genetic medicines, have been emerging as a promising new class of medicine, which confer tremendous flexibility and broader therapeutic utility than any other known drug. At present, the clinical translation of nucleic acids remains challenging due to their labile nature, insufficient delivery efficiency, and potential side effects. Through a fusion of biomolecular sciences with material engineering, pharmaceutics, and immunology, the Li lab explores new biomaterials and nanoparticles to build safe and effective delivery platforms for nucleic acids. The overall objective of Li lab is to develop novel nucleic acid-based vaccines and therapeutics for a range of human health applications including vaccination, immunotherapy, and regenerative medicine.

Drug Development & Disease Diagnostics